AZN - AstraZeneca PLC

NYSE - Nasdaq Real Time Price. Currency in USD
38.57
-0.20 (-0.51%)
As of 11:00AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close38.77
Open38.77
Bid38.56 x 2200
Ask38.57 x 1800
Day's Range38.41 - 38.82
52 Week Range34.38 - 43.30
Volume1,178,266
Avg. Volume5,410,093
Market Cap101.007B
Beta (3Y Monthly)0.56
PE Ratio (TTM)45.38
EPS (TTM)0.85
Earnings DateN/A
Forward Dividend & Yield1.40 (3.46%)
Ex-Dividend Date2019-02-28
1y Target Est46.10
Trade prices are not sourced from all markets
  • AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
    Zacks1 hour ago

    AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why

    AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.

  • Top Ranked Income Stocks to Buy for April 17th
    Zacksyesterday

    Top Ranked Income Stocks to Buy for April 17th

    Top Ranked Income Stocks to Buy for April 17th

  • Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
    Zacks3 days ago

    Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer

    Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.

  • AstraZeneca’s Oncology Portfolio: Growth Trends in 2019
    Market Realist3 days ago

    AstraZeneca’s Oncology Portfolio: Growth Trends in 2019

    Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Oncology portfolio growth trends During AstraZeneca’s (AZN) fourth-quarter earnings investor presentation, the company highlighted the potential of its oncology drug,

  • Reuters3 days ago

    London's FTSE 100 tugged down by miners; IWG lifts midcaps

    (Reuters) - Britain's main index lost ground on Monday as miners and oil majors fell, more than offsetting gains in bank stocks. The FTSE 100 was 0.2 percent lower, lagging its European and Asian counterparts, ...

  • PFE or AZN: Comparing Their Earnings Growth in 2019
    Market Realist6 days ago

    PFE or AZN: Comparing Their Earnings Growth in 2019

    Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Earnings guidance On its fourth-quarter earnings conference call, Pfizer (PFE) said that it expected its 2019 adjusted diluted EPS to be $2.82–$2.92, which doesn’t

  • What Are Analysts Recommending for PFE and AZN?
    Market Realist6 days ago

    What Are Analysts Recommending for PFE and AZN?

    Pfizer or AstraZeneca: Which Is a Better Pick in April?Stock price movementsOn April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37, and 9.04% below its 52-week high of

  • Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
    Zacks6 days ago

    Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

    Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.

  • Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall
    Zacks6 days ago

    Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall

    The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.

  • Here's what to expect from the stock market next month
    Investopedia8 days ago

    Here's what to expect from the stock market next month

    History favors a sustained rally after the strongest first quarter in a decade, but challenges remain as growth slows in the U.S., China and Europe.

  • Is AstraZeneca Stock Worth Buying Before Earnings?
    InvestorPlace8 days ago

    Is AstraZeneca Stock Worth Buying Before Earnings?

    Last year's extreme sentiment fears have abated and now the equity markets are back near all-time highs. This includes stocks like AstraZeneca (NYSE:AZN) as it set a new high late last month. From that standpoint, this is not an obvious entry point into AZN stock, but whether you should buy the stock also depends on a few other factors.Source: Shutterstock Those who want to own AZN shares for the long term can afford to ignore short-term downside risk. But for most other investors who prefer to start an ownership position into a stock in the green should be slightly more surgical than just jumping in at any time.AZN stock is on a tear up 11% in 12 months. But the company will report earnings on April 26 and those events are wild. So this makes buying the stock now a short-term binary bet. Reactions to earnings scorecards are usually more to do with expectations than the actual value of a stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBefore you label me a hater, my caution for AstraZeneca stock here is not a dis against the company itself or its prospects. I am merely concerned with buying into a stock that is not likely to fall soon thereafter. Looking back on its prior reactions to earnings, they are split. * 10 Dow Jones Stocks Holding the Blue Chip Index Back Last quarter, the stock spiked drastically on the results, which left a giant open gap in the chart. Although this does not happen all of the time, Wall Street usually likes to fill these gaps.Since the spike to all-time highs, AZN stock has been drifting lower and testing recent support. If it loses $40 per share, it risks triggering a bearish pattern that would close the gap below. Although this is not a forecast, it is a scenario that could unfold here and investors need to be aware of it.The good news is that $39 per share is a mid-term pivot level and those tend to lend support on the way down. These are zones that the bulls and bears find interesting, so they will fight it out and create price congestion. How to Approach AZN Stock NowSo far my reservation to owning the shares immediately has been technically based. Fundamentally, AZN stock is not cheap as it sells at a price-to-earnings ratio of 47. This is more than three times as expensive as Bristol-Myers Squibb (NYSE:BMY) and twice as expensive as Apple (NASDAQ:AAPL) … to draw absolute and relative comparisons, respectively.Moreover, healthcare and biotech stocks are back in the sights of the political rifles. This is the only current bipartisan consensus topic. Both Democrats and Republicans want to vilify and persecute the drug companies. The rhetoric of both sides involves bringing legislation that would bring down the price of medicine and change the current Health Care Act. * 7 Vulnerable Stocks to Watch On Brexit News and Trade Wars These are nervous times on Wall Street. The S&P 500 has been on an extended run since the December crash and that makes investors nervous. Almost everyone I hear in the media suggests that traders are ready to sell at the first sign of trouble. So the prevailing idea is that we've come too far too fast. For some reason, they didn't say that on the way down, when last year we fell even faster and farther.But for now, we have to respect the collective and be cautious. This is not an obvious time to load up on new positions of AZN stock, even if it means I would miss out on a few upside dollars if it rips. And for those who already own AstraZeneca stock, it's not an alarm to sell out of the position. Furthermore, the options markets offer many ways I can temporarily defend my shares by selling covered calls or buying puts. Doing both would be a dollar neutral strategy.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Medical Marijuana Stocks to Cure Your Portfolio * 8 Best Stocks to Buy for an April Rally * Top 20 Stocks to Buy for 20-Somethings! Compare Brokers The post Is AstraZeneca Stock Worth Buying Before Earnings? appeared first on InvestorPlace.

  • Alkermes Reports Positive Data From Schizophrenia Study
    Zacks8 days ago

    Alkermes Reports Positive Data From Schizophrenia Study

    Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

  • J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?
    Zacks8 days ago

    J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?

    J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.

  • AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
    Zacks8 days ago

    AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer

    AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.

  • PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
    Zacks9 days ago

    PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

    FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

  • Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457
    Zacks9 days ago

    Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

    Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

  • The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
    Zacks10 days ago

    The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

    The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

  • Is AstraZeneca PLC's (LON:AZN) Balance Sheet A Threat To Its Future?
    Simply Wall St.10 days ago

    Is AstraZeneca PLC's (LON:AZN) Balance Sheet A Threat To Its Future?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! There are a number of reasons that attract investors towards large-cap companies such as AstraZeneca PLC (LON:AZN), with a ma...

  • Financial Times10 days ago

    City of London alarmed at EU’s no-deal Brexit equity trading plan

    Fund managers holding European equities are praying that a no-deal Brexit is avoided this week. Europe operates the world’s most integrated cross-border share trading marketplace but the UK’s possible sudden departure from the EU would cleave this network into two: EU and non-EU markets. Today, an asset manager in Paris can ask a London bank to buy a Spanish stock in Madrid.

  • Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
    Zacks12 days ago

    Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

    Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

  • Will Ironwood Suffer From Dependence on Linzess' Progress?
    Zacks13 days ago

    Will Ironwood Suffer From Dependence on Linzess' Progress?

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

  • Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
    Zacks13 days ago

    Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU

    Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

  • Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck
    Zacks13 days ago

    Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck

    The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.

  • Financial Times13 days ago

    Investors Chronicle: Hostelworld. YouGov, AstraZeneca

    Hostelworld is improving its brand recognition while keeping customer acquisition costs well below the targeted range, writes Julia Faurschou. Hostelworld now has a free cancellation policy on all its bookings, which is meant to encourage more budget-minded travellers to book accommodation via the company’s own-brand platform. Chief executive Gary Morrison, who took the role in June last year, said 2018 would be where the company took “the hit” in terms of the impact this policy has on accounting, since it cannot recognise those bookings as revenue until the option to cancel the booking has passed.

  • Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up
    Zacks14 days ago

    Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up

    Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.